ASH: Allogene’s off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field
Excerpt from the Article:
Allogene Therapeutics has linked its off-the-shelf anti-BCMA CAR-T cell therapy to a 60% response rate in a phase 1 trial. The candidate is up against autologous cell therapies that have set the efficacy bar high, but Allogene has off-the-shelf advantages and levers to pull to further improve outcomes.
The original release of data on ALLO-715 last month was overshadowed by news of a death in the phase 1 study. Investigators deemed the death related to progressive myeloma and conditioning regimen, but Allogene’s stock price fell nonetheless. Allogene arrived at the annual meeting of the American Society of Hematology (ASH) with updated data to make its case for ALLO-715.
South San Francisco-based Allogene said it is very pleased with the data. The trial shows Allogene can manufacture ALLO-715 and safely administer it. Efficacy, while short of the bar set by autologous rivals, is a starting point that may be improved on as Allogene moves through and beyond the dose-escalation trial.
Click the button below to continue reading the Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?